RhumbLine Advisers’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $558K | Sell |
|
|||||
|
2025
Q2 | $245K | Sell |
|
|||||
|
2025
Q1 | $229K | Sell |
|
|||||
|
2024
Q4 | $409K | Buy |
|
|||||
|
2024
Q3 | $754K | Sell |
|
|||||
|
2024
Q2 | $1.53M | Buy |
|
|||||
|
2024
Q1 | $2.03M | Buy |
|
|||||
|
2023
Q4 | $1.21M | Buy |
|
|||||
|
2023
Q3 | $744K | Buy |
|
|||||
|
2023
Q2 | $885K | Buy |
|
|||||
|
2023
Q1 | $817K | Buy |
|
|||||
|
2022
Q4 | $1.05M | Buy |
|
|||||
|
2022
Q3 | $365K | Buy |
|
|||||
|
2022
Q2 | $290K | Buy |
|
|||||
|
2022
Q1 | $531K | Buy |
|
|||||
|
2021
Q4 | $674K | Buy |
|
|||||
|
2021
Q3 | $662K | Buy |
|
|||||
|
2021
Q2 | $229K | Buy |
|
|||||
|
2021
Q1 | $254K | Buy |
|